InsiderTradesSIGMA

InsidersTradesSigma

← Executives ★ Sign in to follow

KS

Kintz Samuel

US·SEC (Form 4)

Enliven Therapeutics, Inc.

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

€2m

▼ Sales (12 ops.)

Insider track record

Other

Disclosed buys

0

Disclosed sells

12

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Discover the detailed record of transactions filed by Kintz Samuel. Officer active across 1 company, notably Enliven Therapeutics, Inc.. Aggregated, 23 disclosures have been recorded. Breakdown: 0 buy · 12 sells. Total volume traded: €1.8m. Activity tracked since 25 September 2023. The latest transaction was filed on 19 May 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.

Declarations23 total

▼

PRESIDENT AND CEOExecutives19 May 2025Enliven Therapeutics, Inc.

$82,45337SEC ↗

5,000 shares@ US$16.49063.8% of flowCommon StockSEC:0001415889-25-013992:0

▼

PRESIDENT AND CEOExecutives1 May 2025Enliven Therapeutics, Inc.

$107,00737SEC ↗

5,330 shares@ US$20.07634.9% of flowCommon StockSEC:0001415889-25-012030:0

▼

PRESIDENT AND CEOExecutives17 Apr 2025Enliven Therapeutics, Inc.

$82,09637SEC ↗

5,000 shares@ US$16.41923.7% of flowCommon StockSEC:0001415889-25-011121:0

▼

PRESIDENT AND CEOExecutives17 Mar 2025Enliven Therapeutics, Inc.

$260,32038SEC ↗

12,500 shares@ US$20.825612.4% of flowCommon StockSEC:0001415889-25-008609:0

▼

PRESIDENT AND CEOExecutives18 Oct 2024Enliven Therapeutics, Inc.

$27,72340SEC ↗

924 shares@ US$30.00291.3% of flowCommon StockSEC:0001415889-24-025503:0

▼

PRESIDENT AND CEOExecutives8 Oct 2024Enliven Therapeutics, Inc.

$368,07842SEC ↗

13,167 shares@ US$27.954617.4% of flowCommon StockSEC:0001415889-24-024991:0

▼

PRESIDENT AND CEOExecutives4 Oct 2024Enliven Therapeutics, Inc.

$335,79242SEC ↗

12,206 shares@ US$27.510415.8% of flowCommon StockSEC:0001415889-24-024901:0

▼

PRESIDENT AND CEOExecutives1 Oct 2024Enliven Therapeutics, Inc.

$14,48540SEC ↗

526 shares@ US$27.53710.7% of flowCommon StockSEC:0001415889-24-024671:0

▼

PRESIDENT AND CEOExecutives26 Aug 2024Enliven Therapeutics, Inc.

$274,71838SEC ↗

12,000 shares@ US$22.893212.7% of flowCommon StockSEC:0001415889-24-022512:0

▼

PRESIDENT AND CEOExecutives31 Jul 2024Enliven Therapeutics, Inc.

$62,55540SEC ↗

2,270 shares@ US$27.55733.0% of flowCommon StockSEC:0001415889-24-020687:0

▼

PRESIDENT AND CEOExecutives25 Jul 2024Enliven Therapeutics, Inc.

$93,04240SEC ↗

3,793 shares@ US$24.534.4% of flowCommon StockSEC:0001415889-24-020265:0

▼

PRESIDENT AND CEOExecutives25 Jun 2024Enliven Therapeutics, Inc.

$247,01441SEC ↗

11,422 shares@ US$21.626211.9% of flowCommon StockSEC:0001415889-24-018336:0

◇

PRESIDENT AND CEOExecutives28 May 2024Enliven Therapeutics, Inc.

$13,44022SEC ↗

12,000 shares@ US$1.120.6% of flowCommon StockSEC:0001415889-24-014915:0

◇

PRESIDENT AND CEOExecutives25 Apr 2024Enliven Therapeutics, Inc.

$13,44022SEC ↗

12,000 shares@ US$1.120.6% of flowCommon StockSEC:0001415889-24-011707:0

◇

PRESIDENT AND CEOExecutives11 Apr 2024Enliven Therapeutics, Inc.

$53,43422SEC ↗

47,709 shares@ US$1.122.6% of flowCommon StockSEC:0001415889-24-010828:0

◇

PRESIDENT AND CEOExecutives25 Mar 2024Enliven Therapeutics, Inc.

$13,44022SEC ↗

12,000 shares@ US$1.120.6% of flowCommon StockSEC:0001415889-24-009220:0

◇

PRESIDENT AND CEOExecutives26 Feb 2024Enliven Therapeutics, Inc.

$13,44022SEC ↗

12,000 shares@ US$1.120.6% of flowCommon StockSEC:0001415889-24-005748:0

◇

President and CEOExecutives25 Jan 2024Enliven Therapeutics, Inc.

$13,44022SEC ↗

12,000 shares@ US$1.120.6% of flowCommon StockSEC:0001209191-24-002392:0

◇

President and CEOExecutives26 Dec 2023Enliven Therapeutics, Inc.

$13,44022SEC ↗

12,000 shares@ US$1.120.6% of flowCommon StockSEC:0001209191-23-059908:0

◇

President and CEOExecutives21 Dec 2023Enliven Therapeutics, Inc.

20 shares@ US$1.120.0% of flowCommon StockSEC:0001209191-23-059717:0

◇

President and CEOExecutives20 Dec 2023Enliven Therapeutics, Inc.

$8,71222SEC ↗

7,779 shares@ US$1.120.4% of flowCommon StockSEC:0001209191-23-059433:0

◇

President and CEOExecutives3 Nov 2023Enliven Therapeutics, Inc.

$8,98922SEC ↗

8,026 shares@ US$1.120.4% of flowCommon StockSEC:0001209191-23-054524:0

◇

President and CEOExecutives25 Sept 2023Enliven Therapeutics, Inc.

$13,44030SEC ↗

12,000 shares@ US$1.12100.0% of flowCommon StockSEC:0001209191-23-050616:0

23 of 23 declarations